

Resource Summary Report

Generated by [kravitz2](#) on Aug 9, 2026

pdCas9-NED

RRID:Addgene_109358

Type: Plasmid

Proper Citation

RRID:Addgene_109358

Plasmid Information

URL: <http://www.addgene.org/109358>

Proper Citation: RRID:Addgene_109358

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:29524148](#)

Vector Backbone Description: Backbone Marker:Joung lab; Backbone Size:7636; Vector Backbone:pMLM3705 (Addgene plasmid #47754).; Vector Types:Mammalian Expression, CRISPR; Bacterial Resistance:Ampicillin

Comments: The DNA fragment encoding the effector domain is synthesized by PCR and cloned between the *Ascl* and *PacI* sites of pdCas9-NED to create in-frame fusion between dCas9 (D10A, H840A) and the effector domain. For experiments involving cell lines stably expressing the dCas9-effector domain fusion protein, the coding sequence of the effector domain can be excised from the pdCas9-NED-based recombinant plasmid and transferred into pHAGE EF1? dCas9-NED (Addgene plasmid #109369). Cloning the *Ascl*-*PacI* fragment between the *MluI* and *AsiSI* sites of pHAGE EF1? dCas9-NED preserves the reading frame of the fusion protein (Goubert et al., 2018).

Plasmid Name: pdCas9-NED

Record Creation Time: 20220422T221530+0000

Record Last Update: 20260808T080417+0000

Ratings and Alerts

No rating or validation information has been found for pdCas9-NED.

No alerts have been found for pdCas9-NED.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Sarno F, et al. (2025) Epigenetic editing and epi-drugs: a combination strategy to simultaneously target KDM4 as a novel anticancer approach. Clinical epigenetics, 17(1), 105.

Wu DD, et al. (2023) Targeted epigenetic silencing of UCHL1 expression suppresses collagen-1 production in human lung epithelial cells. Epigenetics, 18(1), 2175522.

Sarno F, et al. (2022) Functional Validation of the Putative Oncogenic Activity of PLAU. Biomedicines, 11(1).

Gjaltema RAF, et al. (2020) KRAB-Induced Heterochromatin Effectively Silences PLOD2 Gene Expression in Somatic Cells and is Resilient to TGF β 1 Activation. International journal of molecular sciences, 21(10).